ANP 2.33% 4.2¢ antisense therapeutics limited

Nice mention...

  1. 270 Posts.
    lightbulb Created with Sketch. 65
    The news is showing the good potential of ANP.

    On the biotech side, McNamee said the team at Altor saw compelling value in Antisense Therapeutics (ASX:ANP), which is currently running phase II trials for its Duchenne Muscular Dystrophy (DMD) treatment.
    The drug also has potential application in the treatment of multiple sclerosis, and while clinical trials have been encouraging the company also has a unique economic profile for a biotech.
    “What we’re really attracted to is the capital requirements to get to market are low, in comparison to other drugs to get it to market,” McNamee said.
    “If the development phase is expensive it’s much easier if you’re a bigger company. If you’re a small company, and you’ve got a phase II or III trial that requires a huge capital outlay, it’s a very difficult proposition.
    “And that’s because investors know there’s most likely another large cap raise on the horizon, so a lot of those companies trade at a healthy discount.”

    https://unauthorised investment adv... analyst thinks the sector has further to run
watchlist Created with Sketch. Add ANP (ASX) to my watchlist
(20min delay)
Mkt cap ! $20.52M
Open High Low Value Volume
4.3¢ 4.3¢ 3.9¢ $65.20K 1.602M

Buyers (Bids)

No. Vol. Price($)
1 24148 4.1¢

Sellers (Offers)

Price($) Vol. No.
4.3¢ 653181 2
View Market Depth
Last trade - 15.55pm 03/04/2020 (20 minute delay) ?
ANP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.